Verapamil inhibits the glucose transport activity of GLUT1

Larry L Louters1, Nathan Stehouwer, Janelle Rekman

  • 1Department of Chemistry & Biochemistry, Calvin College, Grand Rapids, MI, USA.

Insights

Calcium channel blockers like verapamil can cause hyperglycemia by inhibiting the glucose transporter GLUT1. This effect on glucose uptake is independent of calcium levels and may explain toxicity symptoms.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Calcium channel blocker (CCB) toxicity is linked to severe hyperglycemia.
  • The precise mechanisms behind CCB-induced hyperglycemia remain unclear.
  • Glucose transporter 1 (GLUT1) mediates basal and stress-induced glucose uptake.

Purpose of the Study:

  • To investigate the impact of the CCB verapamil on GLUT1 glucose uptake activity.
  • To determine if verapamil affects basal and stress-activated GLUT1 transport.

Main Methods:

  • Utilized L929 fibroblast cells and 2-deoxyglucose to measure glucose uptake.
  • Administered varying doses of verapamil to assess dose-dependent effects.
  • Studied verapamil's action under basal and glucose deprivation stress conditions.

Main Results:

  • Verapamil exhibited a dose-dependent inhibition of GLUT1 glucose uptake.
  • Both basal and stress-activated GLUT1 transport were suppressed by verapamil.
  • Inhibition was reversible and dependent on verapamil presence during stress; calcium levels did not influence verapamil's action.

Conclusions:

  • Verapamil directly inhibits GLUT1 transport activity, independent of calcium modulation.
  • This inhibition of GLUT1 may contribute to the hyperglycemia seen in CCB poisoning.
  • Findings offer a novel mechanistic insight into CCB toxicity.

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Membrane Proteins01:30

Membrane Proteins

Plasma membranes have integral transmembrane proteins involved in facilitated transport. These proteins are collectively referred to as transport proteins, and they function as either channels for the material or as carriers themselves. Channel proteins have hydrophilic domains exposed to the intracellular and extracellular fluids and a hydrophilic channel through their core that provides a hydrated opening for solutes to pass through the membrane layers. Passage through the channel allows...